NO20076197L - Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander - Google Patents
Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstanderInfo
- Publication number
- NO20076197L NO20076197L NO20076197A NO20076197A NO20076197L NO 20076197 L NO20076197 L NO 20076197L NO 20076197 A NO20076197 A NO 20076197A NO 20076197 A NO20076197 A NO 20076197A NO 20076197 L NO20076197 L NO 20076197L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- new
- derivatives useful
- azetidinone derivatives
- hyperlipidemic conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
Abstract
Forbindelser med formel (I): (I) Oppfinnelsen angår 2-azetidinonderivater med formel (I) og farmasøytisk akseptable salter, solvater og prodrug derav, og anvendelse av dem som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemi. Oppfinnelsen angår også fremgangsmåter for fremstilling av dem og farmasøytiske blandinger inneholdende dem.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0501469 | 2005-06-22 | ||
PCT/SE2006/000761 WO2006137792A1 (en) | 2005-06-22 | 2006-06-21 | New 2-azetidinone derivatives useful in the treatment of hyperlipidaemic conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20076197L true NO20076197L (no) | 2008-02-29 |
Family
ID=37570730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20076197A NO20076197L (no) | 2005-06-22 | 2007-12-03 | Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander |
Country Status (18)
Country | Link |
---|---|
US (1) | US20100048529A1 (no) |
EP (1) | EP1896457A4 (no) |
JP (1) | JP2008546769A (no) |
KR (1) | KR20080020687A (no) |
CN (1) | CN101243077A (no) |
AR (1) | AR054482A1 (no) |
AU (1) | AU2006259893A1 (no) |
BR (1) | BRPI0611578A2 (no) |
CA (1) | CA2610102A1 (no) |
EC (1) | ECSP078053A (no) |
IL (1) | IL187737A0 (no) |
MX (1) | MX2007016487A (no) |
NO (1) | NO20076197L (no) |
RU (1) | RU2007147339A (no) |
TW (1) | TW200726761A (no) |
UY (1) | UY29616A1 (no) |
WO (1) | WO2006137792A1 (no) |
ZA (1) | ZA200710603B (no) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE485267T1 (de) * | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
UY29607A1 (es) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
AR057380A1 (es) * | 2005-06-22 | 2007-11-28 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
AR057383A1 (es) * | 2005-06-22 | 2007-12-05 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
MY148538A (en) * | 2005-06-22 | 2013-04-30 | Astrazeneca Ab | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
AR060623A1 (es) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
US20100125059A1 (en) * | 2007-03-06 | 2010-05-20 | Teijin Pharma Limited | 1-biarylazetidinone derivative |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
WO2010100255A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2107548T3 (es) * | 1991-07-23 | 1997-12-01 | Schering Corp | Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion. |
LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5739321A (en) * | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
US5919672A (en) * | 1998-10-02 | 1999-07-06 | Schering Corporation | Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone |
CA2432798C (en) * | 2000-12-20 | 2007-02-27 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
CN1556700A (zh) * | 2001-09-21 | 2004-12-22 | ���鹫˾ | 使用甾醇吸收抑制剂治疗或预防脉管炎的方法 |
GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US6761509B2 (en) * | 2002-07-26 | 2004-07-13 | Jan Erik Jansson | Concrete module for retaining wall and improved retaining wall |
US6960047B2 (en) * | 2002-08-02 | 2005-11-01 | Innovative Technology Application, Inc. | Protection barrier apparatus |
JP5137228B2 (ja) * | 2003-03-07 | 2013-02-06 | メルク・シャープ・アンド・ドーム・コーポレーション | 高コレステロール血症の処置のための置換アゼチジノン化合物、置換アゼチジノン処方物およびそれらの使用 |
US7002008B2 (en) * | 2003-06-16 | 2006-02-21 | Bomi Patel Framroze | Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one |
WO2005046797A2 (en) * | 2003-11-05 | 2005-05-26 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
AU2004308332B2 (en) * | 2003-12-23 | 2008-04-10 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
ATE485267T1 (de) * | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
US20060046996A1 (en) * | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
WO2006039334A1 (en) * | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinations of substituted azetidonones and cb1 antagonists |
AR057383A1 (es) * | 2005-06-22 | 2007-12-05 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
US20070049748A1 (en) * | 2005-08-26 | 2007-03-01 | Uppala Venkata Bhaskara R | Preparation of ezetimibe |
TW200806623A (en) * | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
US7498431B2 (en) * | 2005-12-01 | 2009-03-03 | Bomi Patel Framroze | Process for the preparation of chiral azetidinones |
AR060623A1 (es) * | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
CN101528746A (zh) * | 2006-09-15 | 2009-09-09 | 先灵公司 | 治疗脂质代谢障碍、疼痛、糖尿病和其它障碍的螺环氮杂环丁酮衍生物 |
US20100125059A1 (en) * | 2007-03-06 | 2010-05-20 | Teijin Pharma Limited | 1-biarylazetidinone derivative |
-
2006
- 2006-06-20 AR ARP060102616A patent/AR054482A1/es not_active Application Discontinuation
- 2006-06-21 US US11/993,484 patent/US20100048529A1/en not_active Abandoned
- 2006-06-21 WO PCT/SE2006/000761 patent/WO2006137792A1/en active Application Filing
- 2006-06-21 UY UY29616A patent/UY29616A1/es not_active Application Discontinuation
- 2006-06-21 CN CNA2006800301341A patent/CN101243077A/zh active Pending
- 2006-06-21 MX MX2007016487A patent/MX2007016487A/es not_active Application Discontinuation
- 2006-06-21 EP EP06747950A patent/EP1896457A4/en not_active Withdrawn
- 2006-06-21 KR KR1020087001029A patent/KR20080020687A/ko not_active Application Discontinuation
- 2006-06-21 AU AU2006259893A patent/AU2006259893A1/en not_active Abandoned
- 2006-06-21 CA CA002610102A patent/CA2610102A1/en not_active Abandoned
- 2006-06-21 BR BRPI0611578-0A patent/BRPI0611578A2/pt not_active Application Discontinuation
- 2006-06-21 RU RU2007147339/04A patent/RU2007147339A/ru not_active Application Discontinuation
- 2006-06-21 JP JP2008518083A patent/JP2008546769A/ja not_active Withdrawn
- 2006-06-22 TW TW095122519A patent/TW200726761A/zh unknown
-
2007
- 2007-11-28 IL IL187737A patent/IL187737A0/en unknown
- 2007-12-03 NO NO20076197A patent/NO20076197L/no not_active Application Discontinuation
- 2007-12-05 ZA ZA200710603A patent/ZA200710603B/xx unknown
- 2007-12-26 EC EC2007008053A patent/ECSP078053A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR054482A1 (es) | 2007-06-27 |
JP2008546769A (ja) | 2008-12-25 |
MX2007016487A (es) | 2008-03-07 |
CN101243077A (zh) | 2008-08-13 |
AU2006259893A1 (en) | 2006-12-28 |
ZA200710603B (en) | 2009-09-30 |
EP1896457A4 (en) | 2010-03-10 |
WO2006137792A1 (en) | 2006-12-28 |
CA2610102A1 (en) | 2006-12-28 |
UY29616A1 (es) | 2007-01-31 |
EP1896457A1 (en) | 2008-03-12 |
ECSP078053A (es) | 2008-01-23 |
RU2007147339A (ru) | 2009-07-27 |
US20100048529A1 (en) | 2010-02-25 |
BRPI0611578A2 (pt) | 2011-02-22 |
IL187737A0 (en) | 2008-08-07 |
TW200726761A (en) | 2007-07-16 |
KR20080020687A (ko) | 2008-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20076197L (no) | Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander | |
NO20076196L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
NO20076254L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
NO20076195L (no) | Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer | |
NO20076138L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
NO20076137L (no) | Nye 2-azetidinonderivater og deres anvendelse som kolestrolabsorpsjonsinhibitorer for behandling av hyperlipidemi | |
NO20062583L (no) | Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet | |
NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
NO20062591L (no) | Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet | |
NO20074703L (no) | Antibakterielle piperidinderivater | |
NO20085060L (no) | Triazolpyrazinderivater anvendelige som anti-cancermidler | |
NO20082496L (no) | Pyrazinderivater | |
NO20065456L (no) | Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet | |
TW200833675A (en) | Nicotinamide derivatives | |
NO20050016L (no) | Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen | |
NO20055688L (no) | Organiske forbindelser | |
NO20081217L (no) | Nye benzotiazolonderivater | |
NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
NO20092412L (no) | Hydantoinderivater anvendes som MMP-inhibitorer | |
NO20092476L (no) | Antibakterielle polycykliske ureaforbindelser | |
NO20081729L (no) | Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer | |
NO20085385L (no) | Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav | |
NO20083434L (no) | Benzamid- og heteroarenderivater | |
NO20081554L (no) | Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav | |
NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |